This mirrors the outcome of clinical trials where TNF antagonists worsened the disease [94, 95] and the experience with the use of TNF antagonists in non-MS autoimmune diseases such as Crohn’s disease and rheumatoid arthritis where side effects include clinical onset of MS and isolated demyelinating diseases [102]. Here, TNF is linked to myeloid sarcoma.